Adherence with tobramycin inhaled solution and health care utilization

Becky A. Briesacher, Alexandra L. Quittner, Lisa Saiman, Patricia Sacco, Hassan Fouayzi, Lynne M. Quittell

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Background: Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.Methods: We analyzed 2001-2006 healthcare claims data from 45 large employers. Study subjects had diagnoses of CF and at least 1 prescription for TIS. We measured adherence as the number of TIS therapy cycles completed during the year and categorized overall adherence as: low ≤ 2 cycles, medium >2 to <4 cycles, and high ≥ 4 cycles per year. Interquartile ranges (IQR) were created for health care utilization and logistic regression analysis of hospitalization risk was conducted by TIS adherence categories.Results: Among 804 individuals identified with CF and a prescription for TIS, only 7% (n = 54) received ≥ 4 cycles of TIS per year. High adherence with TIS was associated with a decreased risk of hospitalization when compared to individuals receiving ≤ 2 cycles (adjusted odds ratio 0.40; 95% confidence interval 0.19-0.84). High adherence with TIS was also associated with lower outpatient service costs (IQR: $2,159-$8444 vs. $2,410-$14,423) and higher outpatient prescription drug costs (IQR: $35,125-$60,969 vs. $10,353-$46,768).Conclusions: Use of TIS did not reflect recommended guidelines and may impact other health care utilization.

Original languageEnglish (US)
Article number5
JournalBMC Pulmonary Medicine
Volume11
DOIs
StatePublished - Jan 20 2011

    Fingerprint

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011). Adherence with tobramycin inhaled solution and health care utilization. BMC Pulmonary Medicine, 11, [5]. https://doi.org/10.1186/1471-2466-11-5